期刊文献+

盐酸法舒地尔防治脑血管造影致血管痉挛的临床观察 被引量:2

Clinical observation of hydroxyl fasudil in prevention and treatment of DSA-induced cerebral spasm
下载PDF
导出
摘要 目的观察盐酸法舒地尔防治脑血管造影术所致脑血管痉挛的临床效果。方法将120例行脑血管造影的患者随机分为观察组(60例)和对照组(60例),对照组术前30 min肌内注射苯巴比妥钠0.2 g,观察组在此基础上应用盐酸法舒地尔60mg静脉缓慢滴入,持续至造影后30 min。结果观察组术后2例发生脑血管痉挛,发生率为3.3%;对照组出现脑血管痉挛10例,发生率为16.7%,差异有统计学意义(χ2=4.537,P<0.05)。结论脑血管造影术中静脉滴入盐酸法舒地尔可防治脑血管痉挛的发生,且安全可靠。 Objective To Observe the effect of hydroxyl fasudil in prevention and treatment of DSA - induced cerebral vascular spasm. Methods A total 120 cases of ischemic cerebrovascular patients with digital subtraction angiography (DSA) examination were ran- domly divided into 2 groups (n = 60, in each group) : study group and control group. Besides receiving traditional treatment, 60rag of hy- droxyl fasudil was used as intravenous drip 30 minutes before DSA. The treatment of the control group was similar to those of study group ex- cept for hydroxyl fasudil. Results 2 cases of vascular spasm were observed in study group (3.3%), 10 cases of vascular spasm were ob- served in control group ( 16.7% ). The incidence rate of DSA - induced cerebral vascular spasm in study group was lower than that of control group(x2 = 4.537,P 〈 0.05 ). Conclusion Hydroxyl fasudil can degrade the incidence rate in prevention and treatment of DSA - induced cerebral vascular spasm. Hydroxyl fasudil is safe in clinical application.
出处 《安徽医学》 2012年第7期808-810,共3页 Anhui Medical Journal
基金 阜阳市卫生局科研基金课题(课题编号:06001)
关键词 盐酸法舒地尔 脑血管造影 血管痉挛 Hydroxyl fasudil Digital subtraction angiography Cerebrovascular spasm
  • 相关文献

参考文献8

二级参考文献60

共引文献82

同被引文献26

  • 1张明,孙晓川.法舒地尔的药理作用及其临床应用的研究进展[J].山西医科大学学报,2007,38(4):369-373. 被引量:71
  • 2马小欣,赵慧颖,徐宝华.Rho/Rho激酶与动脉粥样硬化及冠心病的关系[J].中国微循环,2007,11(2):138-141. 被引量:9
  • 3Akihiro Masumoto, Masahiro Mohri, Hiroaki Shimokawa. Sup- pression of Coronary Artery Spasm by the Rho - Kinase Inhibitor Fasudil in Patients With Vasospastic Angina [ J ]. Circulation, 2002, 105:1 545-1 547.
  • 4Surma, M. & L. Wei, & J. J. Shi. Rho kinase as a therapeutic target in cardiovascular disease [ J ]. Future Cardiol, 2011, 7 ( 5 ) : 657 - 671.
  • 5Connolly, J. Aaronson PI. Key role of the RhoA/Rho kinase sys- tem in pulmonary hypertension[J ]. Pulm Pharmacol Ther, 2011, 24(1):1 - 14.
  • 6Zhou Q, Gensch C, Liao JK. Rho - associated coiled - coil - form- ing kinases (ROCKs) ; potential targets for the treatment of atherosclerosis and vascular disease [ J ]. Trends Pharmacol Sci, 2011,32(3):167- 173.
  • 7Amano M, Nakayama M, Kaihuchi K. Rho- Kinase /ROCK: A key regulator of the cytoskeleton and cell polarity[J ]. Cytoskele- ton, 2010, 67(9) : 545 - 554.
  • 8Garcia MC, Ray DM, Lackford B, et al. Arachidonic acid stimu- lates cell adhesion through a novel p38 MAPK - RhoA signaling pathway that involves heat shock protein 27 [J ]. J Biol Chem, 2009, 284(31 ) : 936 - 945.
  • 9Hideki Ishii, Tetsuya Amano, Tatsuaki Matsubara. Pharmacologi- cal Prevention of Peri -, and Post - Procedural Myocardial Injury in Percutaneous Coronary Intervention [ J ]. Current Cardiology Reviews, 2008, 4 : 223 - 230.
  • 10贺勇,郑明霞,崔凯军,张立,冯沅,胡宏德,黄德嘉.冠脉介入治疗后肌钙蛋白升高的原因及其临床意义[J].四川大学学报(医学版),2008,39(1):126-129. 被引量:8

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部